Growth
Which Telehealth Categories Have the Best Margins Beyond GLP-1?
With large-scale compounded GLP-1 winding down, the question every operator is asking is where the durable margin is next. Here is how the leading categories compare on retention, protocol simplicity, and regulatory exposure.
Quick answer
The strongest categories beyond GLP-1 are hormone optimization (TRT and menopause HRT), peptide therapy, and hair loss. They combine recurring compounded refills, simple protocols, and — for peptides and hair loss — no controlled-substance scheduling. TRT carries higher retention but a Schedule III requirement. The best margin is durable margin: categories that refill monthly and are not exposed to a single FDA decision.
Key takeaways
- Durable margin comes from recurring compounded refills, not from any single high-ticket sale.
- Hormone optimization (TRT, HRT) offers the highest retention because patients stay on protocol for years.
- Peptides and hair loss compounds are non-controlled, which simplifies prescribing and provider licensing.
- TRT delivers strong economics but testosterone is Schedule III, so controlled-substance rules apply.
- Publicly traded DTC health companies report gross margins in the mid-to-high 70s, a useful ceiling reference.
- The safest margin strategy is breadth — running two or three categories so no single FDA decision resets your business.
The strongest telehealth categories beyond GLP-1 are hormone optimization (TRT and menopause HRT), peptide therapy, and hair loss. They share the trait that actually builds margin — recurring compounded refills — and, for peptides and hair loss, they avoid controlled-substance scheduling entirely. TRT carries the highest retention but a Schedule III requirement. The real answer is that the best margin is durable margin: categories that refill monthly and do not hinge on one FDA decision.
The GLP-1 wind-down has turned "what's next" into the most common operator question of 2026. This post compares the leading answers on the dimensions that actually determine profit — retention, protocol simplicity, and regulatory exposure — rather than on headline price. For the strategic frame behind it, how diversification protects your margins covers why breadth beats a single anchor.
What Telehealth Categories Have the Best Margins Beyond GLP-1?
Hormone optimization, peptides, and hair loss lead. Hormones (TRT, HRT) offer the highest retention because patients stay on protocol for years; peptides and hair loss are non-controlled, which lowers prescribing friction. All three refill on a recurring schedule, which is where compounded-Rx margin actually comes from — not from any single high-ticket sale.
The instinct after GLP-1 is to hunt for the next high-margin molecule. That framing misleads. Margin in DTC telehealth is a function of retention times per-refill contribution, not sticker price. A category that a patient stays on for two years at a modest monthly margin generates far more lifetime value than a one-time sale at a high one. So the right question is not "what has the best margin" but "what has the best durable margin" — and the answer favors categories that are clinically appropriate for long-term, recurring use. How compounded-Rx pricing and margins work unpacks the per-order math.
How Do the Leading Categories Compare?
Each category trades retention against regulatory friction. Hormones win on retention but carry controlled-substance handling for testosterone; peptides and hair loss are simpler to prescribe but each has its own regulatory nuance. The comparison below is directional — your realized numbers depend on formulary, states, and pharmacy — but the shape holds.
| Category | Retention profile | Controlled substance? | Margin driver |
|---|---|---|---|
| TRT (men's hormone optimization) | High — multi-year protocols | Yes — testosterone is Schedule III | Recurring injections/creams, high LTV |
| HRT / menopause (women's hormones) | High — long-term therapy | Mostly no (bioidentical estradiol/progesterone) | Recurring compounded refills |
| Peptides (BPC-157, Sermorelin, PT-141, NAD+) | Medium–high | Generally no | Recurring refills, low prescribing friction |
| Hair loss (finasteride/minoxidil compounds) | Medium–high | No | Low-cost recurring refills, broad demand |
| Medical weight loss (non-GLP-1 adjuncts) | Medium | Varies | Bridges GLP-1 patients into a durable protocol |
The pattern to read out of the table: the categories with the least regulatory friction (peptides, hair loss) are the easiest to add, and the categories with the highest retention (hormones) are the most valuable to hold. A balanced clinic runs some of each.
Why Is Hormone Optimization the Retention Leader?
TRT and menopause HRT retain best because they treat chronic conditions with protocols measured in years, not weeks. A patient optimized on testosterone or bioidentical hormones has a clinical reason to refill monthly for a long time, and that duration is exactly what converts a modest per-refill margin into strong lifetime value.
The catch is on the men's side: testosterone is an anabolic steroid and a Schedule III controlled substance under the DEA's controlled substance schedules. Prescribing it via telehealth means your provider needs the right DEA registration and you operate under controlled-substance rules — a real operational load that non-controlled categories avoid. Menopause HRT is generally lighter, since bioidentical estradiol and progesterone are not controlled. Operators often start with the non-controlled side and add TRT once their compliance workflow is mature. How to open a virtual TRT clinic covers that path in detail.
Are Peptides and Hair Loss Worth Adding?
Yes, primarily because they are low-friction to prescribe and refill on a recurring basis. Most peptides (BPC-157, CJC-1295/Ipamorelin, Sermorelin, PT-141, NAD+) and hair loss compounds (topical finasteride/minoxidil) are not controlled substances, so they do not carry the DEA overhead that testosterone does, which makes them fast to layer onto an existing clinic.
The nuance is regulatory, not commercial. Peptide compounding sits in an evolving FDA area — some peptides face restrictions on the bulk substances a 503A pharmacy may use, governed by the FDA's compounding laws and policies. So the discipline is per-molecule: confirm with your compounding pharmacy and counsel that each specific peptide is currently compoundable, rather than treating "peptides" as one settled category. Hair loss is the simplest of all — broad demand, low compound cost, non-controlled — which is why it is a common first diversification. Setting up a peptide telehealth clinic goes deeper on the operational side.
What Gross Margin Is Realistic?
Publicly traded DTC health companies have reported gross margins in the mid-to-high 70s percent range, which is a useful ceiling reference rather than a promise. Your realized margin sits below that headline once you account for compound cost, shipping, provider pay, and platform fees — and it varies more by category and cold-chain needs than most founders expect.
Two levers move your number more than the category choice itself:
- Retention over price. A category that refills monthly at a moderate margin beats a one-time high-margin sale. Prioritize protocols patients stay on.
- Fulfillment cost discipline. Injectable peptides and hormones need cold-chain shipping, which eats margin if mishandled; simple oral or topical compounds do not. Match your category mix to what you can fulfill efficiently.
The takeaway: chase durable, recurring margin, and treat the mid-70s figure as the theoretical top of the range, not a plan.
The Real Strategy Is Breadth, Not a New Anchor
The mistake hiding inside "what replaces GLP-1" is the assumption that you need one new anchor category. Swapping one dependency for another just recreates the concentration risk that made the GLP-1 wind-down painful. The durable move is breadth: run two or three complementary categories so no single FDA or supply decision can reset your business.
Breadth is only affordable if your stack makes adding a category cheap. If every new category means a new pharmacy integration, a new storefront build, or a migration, diversification is theoretical. This is where an overlay/rail model earns its place: because it sits on top of the compounding pharmacy you already use and keeps your storefront and patient data as the system of record, adding hormones, peptides, or hair loss is a formulary and routing change — not a rebuild. That is what turns "diversify beyond GLP-1" from a slogan into something you can actually execute. For the weight-loss-specific version of this, see running weight loss after the GLP-1 cliff.
Key Takeaways
- Durable margin comes from recurring compounded refills, not from any single high-ticket sale.
- Hormone optimization (TRT, HRT) has the highest retention because patients stay on protocol for years.
- Peptides and hair loss compounds are generally non-controlled, which lowers prescribing and licensing friction.
- TRT economics are strong, but testosterone is Schedule III, so controlled-substance rules apply.
- Public DTC health companies report mid-to-high-70s gross margins — a ceiling reference, not a guarantee.
- The safest strategy is breadth: run two or three categories so no single FDA decision resets your business.
Frequently Asked Questions
What is the highest-retention telehealth category?
Hormone optimization — TRT for men and HRT for menopausal women — tends to have the highest retention, because these are long-term protocols patients stay on for years. High retention drives lifetime value, so even a moderate monthly margin compounds into strong economics. The tradeoff is that testosterone is Schedule III, so you inherit DEA and controlled-substance requirements that non-controlled categories avoid.
Are peptides a good telehealth category after GLP-1?
Peptides like BPC-157, Sermorelin, PT-141, and NAD+ are a popular diversification because most are not controlled, which simplifies prescribing and licensing, and refills are recurring. The caution is regulatory: peptide compounding is an evolving FDA area and some peptides face bulk-substance restrictions, so vet each molecule with your pharmacy and counsel rather than assuming the whole category is settled.
What gross margin can a telehealth clinic expect on compounded meds?
Vertically integrated DTC companies have reported mid-to-high-70s percent gross margins in public filings — a ceiling reference, not a guarantee. Realized margin depends on compound cost, shipping (especially cold chain), provider pay, and platform fees. The lever that matters more than the headline is retention: a category that refills monthly at a modest margin beats a one-time sale at a high one.
Should I replace GLP-1 or add categories around it?
Add around it. Treating this as a single swap just recreates the concentration risk. The durable move is breadth: run GLP-1 while viable alongside two or three adjacent categories so no single decision resets your business. Breadth is only cheap if your stack lets you add a category as a formulary change rather than a rebuild.
neolife is the fulfillment rail that sits on top of the compounding pharmacy you already use — so adding TRT, peptides, hormones, or hair loss is a routing and formulary change, not a rebuild, and no single category decision can reset your business. If you want to diversify beyond GLP-1 without re-integrating your stack each time, talk to us. This post is educational and not legal or medical advice; consult qualified counsel and your pharmacy before making formulary decisions.
Primary sources
Frequently asked questions
What is the highest-retention telehealth category?
Hormone optimization — TRT for men and HRT for menopausal women — tends to have the highest retention, because these are long-term protocols patients stay on for years rather than weeks. High retention is what drives lifetime value, so even a moderate monthly margin compounds into strong unit economics. The tradeoff is that testosterone is a Schedule III controlled substance, so you inherit DEA registration and controlled-substance prescribing requirements that non-controlled categories avoid.
Are peptides a good telehealth category after GLP-1?
Peptides such as BPC-157, CJC-1295/Ipamorelin, Sermorelin, PT-141, and NAD+ are a popular diversification because most are not controlled substances, which simplifies prescribing and provider licensing. Margins on compounded peptides can be strong and refills are recurring. The caution is regulatory: peptide compounding sits in an evolving FDA area, and some peptides face bulk-substance restrictions, so vet each molecule with your pharmacy and counsel rather than assuming the whole category is settled.
What gross margin can a telehealth clinic expect on compounded meds?
Vertically integrated DTC telehealth companies have reported gross margins in the mid-to-high 70s percent range in public filings, which is a useful ceiling reference rather than a guarantee. Your realized margin depends on compound cost, shipping (especially cold chain for injectables), provider compensation, and platform fees. The lever that matters more than the headline percentage is retention: a category that refills monthly at a modest margin beats a one-time sale at a high one.
Should I replace GLP-1 or add categories around it?
Add around it. The mistake is treating this as a single swap from one anchor category to another, which just recreates the concentration risk. The durable move is breadth: run GLP-1 while it is viable alongside two or three adjacent categories — hormones, peptides, hair loss — so no single FDA or supply decision resets your business. Breadth is only cheap if your stack lets you add a category as a formulary change rather than a rebuild.
This article is operator education, not medical, legal, or tax advice. Telehealth and pharmacy regulation vary by state and product and change frequently. Verify the specifics for your business with qualified counsel and your pharmacy partner.